Drug Trial Radar · NCT03822559
A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension
Last checked: Nov 20, 2026Latest source record: Jul 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
219
Actual
Start
Jan 20, 2019
Primary completion
Apr 4, 2023
Study completion Apr 4, 2023
Sponsor
- Lead sponsor
- Santen Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 30, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to investigate whether the IOP (intraocular pressure) -lowering effect of DE-111A (preservative-free fixed dose combination of 0.0015% tafluprost and 0.5% timolol eye drops, administered one drop a time, once daily for 3 months) is superior to the monotherapy of tafluprost 0.0015% eye drops administered one drop a time, once daily for 3 months) in subjects with open-angle glaucoma or ocular hypertension in China as well as comparison of safety.
Conditions
- Open-angle Glaucoma, Ocular Hypertension
Interventions
A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mLDrug
One drop a time, once daily administration of DE-111A eye drops in the affected eye(s) at 8:00 am (±1h) for 3 months.
A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mLDrug
One drop a time, once daily administration of preservative-free 0.0015% tafluprost eye drops in the affected eye(s) at 8:00 (±1h) for 3 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the average diurnal IOP (intraocular pressure)Time frame: Three months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Aier Eye Hospital Group Co., Ltd Changsha Aier Eye Hospital
Changsha, China
Eye & Ent Hospital of Fudan University
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.